Patients with TP53 mutations respond poorly and relapse early after conventional chemotherapy (2-year OS 12.8–14%) [98]; in addition, they respond poorly to azacitidine–venetoclax (median OS 1.9 months for relapsed/refractory TP53-mutated AML) [95]. The gene discussed is TP53; the disease is acute myeloid leukemia.